SG11201901961SA - Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x - Google Patents
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor xInfo
- Publication number
- SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA
- Authority
- SG
- Singapore
- Prior art keywords
- coagulation factor
- bleeding
- international
- activated
- recognizes
- Prior art date
Links
- 108010076282 Factor IX Proteins 0.000 title abstract 5
- 108010014173 Factor X Proteins 0.000 title abstract 4
- 229940105774 coagulation factor ix Drugs 0.000 title abstract 4
- 102100029117 Coagulation factor X Human genes 0.000 title abstract 3
- 229940105756 coagulation factor x Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000013831 Coagulation factor IX Human genes 0.000 title 2
- 230000000740 bleeding effect Effects 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111111111H11111110111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/047813 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 39/395 (2006.01) A61P 7/04 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/JP2017/031933 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 05 September 2017 (05.09.2017) patent (Rule 4.17(ii)) (25) Filing Language: English Published: (26) Publication Language: English — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/383,933 06 September 2016 (06.09.2016) US 62/437,281 21 December 2016 (21.12.2016) US 62/485,514 14 April 2017 (14.04.2017) US (71) Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543 (JP). F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, Basel, CH4070 (CH). (72) Inventors: YONEYAMA, Koichiro; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-1, Nihon- bashi-Muromachi 2-chome, Chuo-ku, Tokyo, 1038324 (JP). SCHMITT, Christophe; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel, CH4070 (CH). = (74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RS, RU, RW, SA, QA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated (84) States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, protection GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 en (54) Title: METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR - ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FAC- GC TOR X IN C (57) : An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for ---- preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that GC by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation 1-1 © factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X N according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented 0 and/or treated more effectively.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383933P | 2016-09-06 | 2016-09-06 | |
| US201662437281P | 2016-12-21 | 2016-12-21 | |
| US201762485514P | 2017-04-14 | 2017-04-14 | |
| PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901961SA true SG11201901961SA (en) | 2019-04-29 |
Family
ID=61561893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901961SA SG11201901961SA (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11352438B2 (en) |
| EP (2) | EP3509637B1 (en) |
| JP (3) | JP7125932B2 (en) |
| KR (2) | KR102560808B1 (en) |
| CN (1) | CN109661241A (en) |
| AU (2) | AU2017325240B9 (en) |
| BR (1) | BR112019003989A2 (en) |
| CA (1) | CA3035327A1 (en) |
| CR (1) | CR20190162A (en) |
| ES (1) | ES3000618T3 (en) |
| IL (1) | IL265144B2 (en) |
| MA (1) | MA46200A (en) |
| MX (1) | MX2019002510A (en) |
| MY (1) | MY209831A (en) |
| PL (1) | PL3509637T3 (en) |
| RU (1) | RU2766233C2 (en) |
| SG (1) | SG11201901961SA (en) |
| TW (1) | TWI786061B (en) |
| UA (1) | UA129116C2 (en) |
| WO (1) | WO2018047813A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| RU2620071C2 (en) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function |
| FR3038517B1 (en) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
| EP3395835B1 (en) | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
| TWI820000B (en) | 2016-04-28 | 2023-11-01 | 日商中外製藥股份有限公司 | Antibody-containing preparations |
| JP7125932B2 (en) | 2016-09-06 | 2022-08-25 | 中外製薬株式会社 | Methods of Using Bispecific Antibodies Recognizing Coagulation Factor IX and/or Activated Coagulation Factor IX and Coagulation Factor X and/or Activated Coagulation Factor X |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| AR113816A1 (en) | 2017-11-01 | 2020-06-17 | Chugai Pharmaceutical Co Ltd | VARIANTS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY |
| ES3050257T3 (en) | 2017-11-15 | 2025-12-19 | Novo Nordisk As | Factor x binders enhancing fx activation |
| FR3082427B1 (en) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | COMBINATION OF FACTOR VII AND A BISPECIFIC ANTIBODY ANTI-FACTORS IX AND X |
| CN113453757B (en) | 2018-12-21 | 2024-06-28 | 科马布有限公司 | FIXaxFX bispecific antibodies with a common light chain |
| JP6836696B1 (en) * | 2019-10-11 | 2021-03-03 | 中外製薬株式会社 | A pharmaceutical composition used for the prevention and / or treatment of acquired hemophilia A, and a product containing the pharmaceutical composition. |
| TW202207984A (en) * | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition |
| USD967377S1 (en) | 2020-10-08 | 2022-10-18 | Samsung Electronics Co., Ltd. | Air purifier |
| USD1074966S1 (en) | 2020-10-08 | 2025-05-13 | Samsung Electronics Co., Ltd. | Air purifier |
| CN118414166A (en) | 2021-12-01 | 2024-07-30 | 中外制药株式会社 | Method for preparing a preparation containing an antibody |
| KR102868672B1 (en) | 2022-03-02 | 2025-10-14 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecific antibodies every second week |
| KR102839278B1 (en) | 2022-03-02 | 2025-07-30 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecific antibodies once monthly |
| KR102839225B1 (en) * | 2022-03-02 | 2025-07-29 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecific antibodies once weekly |
| WO2024261245A1 (en) | 2023-06-23 | 2024-12-26 | Novo Nordisk Health Care Ag | Methods of administering fviii mimetic bispecific antibodies once every second month |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| KR100236375B1 (en) | 1989-12-11 | 1999-12-15 | 오트리브 데이비스 더블유 | Pharmaceutical compositions and kit for antibody targeting of diagnostic or therapeutic agents |
| TW212184B (en) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| JPH05184383A (en) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | Bispecific antibody |
| JPH05199894A (en) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | Bi-specific antibody and antibody-containing medicine |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH05304992A (en) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | Hybridoma-monoclonal antibody and medicine containing antibody |
| JPH06104071A (en) | 1991-08-30 | 1994-04-15 | Jasco Corp | Heating element ceramics welding method |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| JPH05203652A (en) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | Antibody enzyme immunoassay |
| JPH05213775A (en) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa antibody |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DK0672142T3 (en) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalent and multi-specific binding proteins as well as their preparation and use |
| JPH08509612A (en) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | Transgenic non-human animal capable of producing heterologous antibody |
| WO1995001571A1 (en) | 1993-07-01 | 1995-01-12 | Baxter Diagnostics Inc. | Process for the preparation of factor x depleted plasma |
| FR2707189B1 (en) | 1993-07-09 | 1995-10-13 | Gradient Ass | Method for treating combustion residues and installation for implementing said method. |
| HU220347B (en) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Composition for the specific coagulation of vasculature |
| HU221385B1 (en) | 1994-07-13 | 2002-09-28 | Chugai Pharmaceutical Co Ltd | Reconstituted human antibody against human interleukin-8 |
| JPH10511085A (en) | 1994-12-02 | 1998-10-27 | カイロン コーポレイション | Methods for promoting an immune response using bispecific antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
| MA24512A1 (en) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS |
| JP3032287U (en) | 1996-06-10 | 1996-12-17 | 幸喜 高橋 | Human form |
| JPH10165184A (en) | 1996-12-16 | 1998-06-23 | Tosoh Corp | Methods for producing antibodies, genes and chimeric antibodies |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (en) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| ATE512225T1 (en) | 1998-04-03 | 2011-06-15 | Chugai Pharmaceutical Co Ltd | HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND METHOD FOR CONSTRUCTING SUCH HUMANIZED ANTIBODY. |
| AT411997B (en) | 1999-09-14 | 2004-08-26 | Baxter Ag | FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES |
| WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| US7732133B2 (en) | 2000-07-17 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Screening methods for biologically active ligands |
| JP5291279B2 (en) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | A collection of repetitive proteins containing repetitive modules |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| JP2004526419A (en) | 2000-10-16 | 2004-09-02 | フィロス インク． | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ATE430580T1 (en) | 2001-10-25 | 2009-05-15 | Genentech Inc | GLYCOPROTEIN COMPOSITIONS |
| DE10156482A1 (en) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispecific antibody molecule |
| WO2003087163A1 (en) | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| EP1505148B1 (en) | 2002-04-26 | 2009-04-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for agonistic antibodies |
| AU2003250074B2 (en) | 2002-07-18 | 2010-09-09 | Merus N.V. | Recombinant production of mixtures of antibodies |
| JPWO2004060919A1 (en) | 2002-12-26 | 2006-05-11 | 中外製薬株式会社 | Agonist antibodies against heteroreceptors |
| WO2004065611A1 (en) | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibdoy |
| JP4607010B2 (en) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | Protein-containing stabilized preparation |
| GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
| JP4794301B2 (en) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | Antibody production method |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (en) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US20080075712A1 (en) | 2003-10-14 | 2008-03-27 | Kunihiro Hattori | Double Specific Antibodies Substituting For Functional Proteins |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| JP4460414B2 (en) | 2004-10-06 | 2010-05-12 | 日本電信電話株式会社 | Sphygmomanometer |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DK1876236T3 (en) | 2005-04-08 | 2014-10-20 | Chugai Pharmaceutical Co Ltd | Antibody as a functional replacement for blood coagulation factor VIII |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN105177091A (en) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
| CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
| PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
| KR101856792B1 (en) | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | Polypeptide modification method for purifying polypeptide multimers |
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| CN103037893A (en) | 2010-06-14 | 2013-04-10 | 帕昂德国有限公司 | Treatment of coagulopathy with hyperfibrinolysis |
| RU2620071C2 (en) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function |
| JP5859148B2 (en) | 2012-03-08 | 2016-02-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Aβ antibody preparation |
| KR20160070163A (en) | 2013-11-04 | 2016-06-17 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation |
| TWI831106B (en) * | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII |
| WO2016164708A1 (en) | 2015-04-10 | 2016-10-13 | Adimab, Llc | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
| MX2017010734A (en) | 2015-04-17 | 2017-12-04 | Hoffmann La Roche | Combination therapy with coagulation factors and multispecific antibodies. |
| JP2018123055A (en) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | Pharmaceutical composition used for prevention and / or treatment of blood coagulation factor XI (FXI) abnormality, comprising a multispecific antigen-binding molecule that substitutes for the function of blood coagulation factor VIII (FVIII) |
| JOP20170017B1 (en) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | Pharmaceutical composition comprising bispecific antibody constructs |
| TWI820000B (en) | 2016-04-28 | 2023-11-01 | 日商中外製藥股份有限公司 | Antibody-containing preparations |
| JP7125932B2 (en) | 2016-09-06 | 2022-08-25 | 中外製薬株式会社 | Methods of Using Bispecific Antibodies Recognizing Coagulation Factor IX and/or Activated Coagulation Factor IX and Coagulation Factor X and/or Activated Coagulation Factor X |
| US20210107994A1 (en) | 2017-03-31 | 2021-04-15 | Public University Corporation Nara Medical University | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
| AR113816A1 (en) | 2017-11-01 | 2020-06-17 | Chugai Pharmaceutical Co Ltd | VARIANTS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY |
| TW202207984A (en) | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition |
-
2017
- 2017-09-05 JP JP2019511669A patent/JP7125932B2/en active Active
- 2017-09-05 MX MX2019002510A patent/MX2019002510A/en unknown
- 2017-09-05 EP EP17848753.4A patent/EP3509637B1/en active Active
- 2017-09-05 UA UAA201902899A patent/UA129116C2/en unknown
- 2017-09-05 TW TW106130277A patent/TWI786061B/en active
- 2017-09-05 AU AU2017325240A patent/AU2017325240B9/en active Active
- 2017-09-05 BR BR112019003989A patent/BR112019003989A2/en unknown
- 2017-09-05 SG SG11201901961SA patent/SG11201901961SA/en unknown
- 2017-09-05 MY MYPI2019001147A patent/MY209831A/en unknown
- 2017-09-05 CA CA3035327A patent/CA3035327A1/en active Pending
- 2017-09-05 CR CR20190162A patent/CR20190162A/en unknown
- 2017-09-05 PL PL17848753.4T patent/PL3509637T3/en unknown
- 2017-09-05 EP EP24214702.3A patent/EP4491224A3/en active Pending
- 2017-09-05 KR KR1020197009689A patent/KR102560808B1/en active Active
- 2017-09-05 US US16/330,269 patent/US11352438B2/en active Active
- 2017-09-05 IL IL265144A patent/IL265144B2/en unknown
- 2017-09-05 CN CN201780054106.1A patent/CN109661241A/en active Pending
- 2017-09-05 RU RU2019109464A patent/RU2766233C2/en active
- 2017-09-05 MA MA046200A patent/MA46200A/en unknown
- 2017-09-05 ES ES17848753T patent/ES3000618T3/en active Active
- 2017-09-05 KR KR1020237025275A patent/KR20230117462A/en not_active Withdrawn
- 2017-09-05 WO PCT/JP2017/031933 patent/WO2018047813A1/en not_active Ceased
-
2022
- 2022-05-31 US US17/828,752 patent/US20220315667A1/en not_active Abandoned
- 2022-08-15 JP JP2022129184A patent/JP2022166174A/en active Pending
-
2023
- 2023-01-19 US US18/156,559 patent/US20230159658A1/en not_active Abandoned
- 2023-09-14 US US18/466,900 patent/US20240052058A1/en not_active Abandoned
-
2024
- 2024-07-17 AU AU2024204924A patent/AU2024204924A1/en active Pending
- 2024-08-15 JP JP2024135511A patent/JP2024161483A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201801401UA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells |